DOI 10.1016/j.clml.2026.03.010
Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.
Аннотация
BACKGROUND
Lisaftoclax is a novel BCL-2 inhibitor. This phase 1 trial (NCT03913949) evaluated the safety and preliminary efficacy of lisaftoclax in Chinese patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and other non-Hodgkin lymphomas (NHL).
PATIENTS AND
METHODS
Lisaftoclax was administered orally in 28-day cycles, targeting daily doses of 20-800 mg for up to 24 cycles, using a daily ramp-up to minimize tumor lysis syndrome (TLS) risk. Patients with previous resistance to a BCL-2 inhibitor or exposure to a BCL-2 inhibitor in the most recent treatment line were excluded. Among 51 enrolled patients, 14 had CLL/SLL, 13 mantle cell lymphoma (MCL), and 4 marginal zone lymphoma (MZL).
RESULTS
The maximum tolerated dose of lisaftoclax was not reached; neither dose-limiting toxicity nor TLS was observed. Common adverse events included anemia, neutropenia, and thrombocytopenia. Significant antitumor activity was observed in CLL/SLL (overall response rate [ORR] 71.4%, complete response [CR] 28.6%); MCL (ORR 50.0%, CR 20.0%); and MZL (ORR 50.0%, CR 0). Median progression-free survival was 7.9 (95% CI, 4.9-14.1) months for all patients and 18.6 (95% CI, 8.4-not reached [NR]) and 7.9 (95% CI, 2.0-NR) months for those with CLL/SLL and MCL, respectively. The median overall survival was NR (95% CI, 26.2-NR) for all patients.
CONCLUSION
Lisaftoclax has a manageable safety profile and induces durable responses in R/R CLL/SLL and NHL.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.